Xeloda, Capecitabine Newswire

Xeloda, Capecitabine Newswire

Comprehensive Real-Time News Feed for Xeloda, Capecitabine (generic).

Results 1 - 20 of 112 in Xeloda, Capecitabine (generic)

  1. Hikma Pharmaceuticals launches generic cancer tablets in USRead the original story w/Photo

    Wednesday Jul 20 | Live Charts

    Hikma Pharmaceuticals said its wholly-owned US affiliate, West-Ward Pharmaceuticals has launched generic cancer treatment tablets in the US. The Capecitabine tablets, which are the generic equivalents to Xeloda tablets, are indicated for adjuvant treatment in patients with Dukes' C colon cancer, as monotherapy in metastatic colorectal cancer, and in combination with docetaxel or as monotherapy in patients with metastatic breast cancer.

    Comment?

  2. ESOPEC: prospective randomized controlled multicenter phase III trial ...Read the original story w/Photo

    Monday Jul 18 | BioMed Central

    Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for combined modality treatment of patients with localized esophageal adenocarcinoma. However, head-to-head comparisons of neoadjuvant chemoradiation and perioperative chemotherapy applying contemporary treatment protocols are lacking.

    Comment?

  3. World China, US and Japan Drugs for Treatment of Breast Cancer Market ...Read the original story

    Monday Jul 11 | Emailwire.com

    'China, US and Japan Drugs for Treatment of Breast Cancer Market Research Report to 2020' Purchase This Report by calling ResearchnReports.com at +1-888-631-6977. The China, US and Japan Drugs for Treatment of Breast Cancer Market industry had made research and come up with a report that focuses on the major players in the China, US and Japan Drugs for Treatment of Breast Cancer Market throughout the world.

    Comment?

  4. World Global and China Drugs for Treatment of Breast Cancer Market...Read the original story

    Monday Jul 11 | Emailwire.com

    'Global and China Drugs for Treatment of Breast Cancer Research Report to 2020' Purchase This Report by calling ResearchnReports.com at +1-888-631-6977. The Global and China Drugs for Treatment of Breast Cancer market had made research and come up with a report that focuses on the major players in the Global and China Drugs for Treatment of Breast Cancer market throughout the world.

    Comment?

  5. Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patientsRead the original story w/Photo

    Monday Jul 4 | Medical News

    Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. "The rationale of postoperative chemoradiotherapy after preoperative chemotherapy is to combine systemic and loco-regional treatments to reduce the risk of recurrent disease and improve outcomes," said the study's principal investigator Professor Marcel Verheij from the Netherlands Cancer Institute.

    Comment?

  6. Chemoradiotherapy after surgery for gastric cancer shows similar...Read the original story w/Photo

    Friday Jul 1 | Medical News Today

    Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. "The rationale of postoperative chemoradiotherapy after preoperative chemotherapy is to combine systemic and loco-regional treatments to reduce the risk of recurrent disease and improve outcomes," said the study's principal investigator Professor Marcel Verheij from the Netherlands Cancer Institute.

    Comment?

  7. Chemoradiotherapy after surgery for GC shows similar outcomes to post-operative chemotherapyRead the original story w/Photo

    Wednesday Jun 29 | EurekAlert!

    Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. "The rationale of postoperative chemoradiotherapy after preoperative chemotherapy is to combine systemic and loco-regional treatments to reduce the risk of recurrent disease and improve outcomes," said the study's principal investigator Professor Marcel Verheij from the Netherlands Cancer Institute.

    Comment?

  8. Cascadian Therapeutics Receives ONT-380 Fast Track Designation from...Read the original story w/Photo

    Tuesday Jun 28 | Drugs.com

    Cascadian Therapeutics , a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug Administration . The Company is actively recruiting patients for a randomized, double-blind, placebo-controlled Phase 2 study, known as HER2CLIMB, evaluating ONT-380 in combination with trastuzumab and capecitabine for patients with advanced HER2+ metastatic breast cancer.

    Comment?

  9. Role of nutritional status and intervention in oesophageal cancer...Read the original story

    Jun 21, 2016 | British Journal of Cancer

    We aimed to identify nutritional prognostic factors and survival outcomes associated with nutritional intervention in the SCOPE1 trial. − cetuximab.

    Comment?

  10. Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data and...Read the original story

    Jun 13, 2016 | BioSpace

    Cascadian Therapeutics , a clinical-stage biopharmaceutical company, will present clinical data from the Company's ongoing Phase 1b studies, including updated clinical data from the study of ONT-380 in combination with trastuzumab and capecitabine , and a review of the recent ASCO data from the ONT-380 combination with T-DM1, at today's Corporate Update and R&D Day in New York City. ONT-380 is an oral, highly selective small molecule HER2 inhibitor being studied as a combination therapy to treat HER2+ locally advanced or metastatic breast cancer, including patients with brain metastases.

    Comment?

  11. [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) ...Read the original story

    Jun 9, 2016 | CiteULike

    Incidence and mortality rates of colorectal malignancies in the Czech Republic are one of the highest in the world since over 7,500 patients are diagnosed yearly. About 25% of patients are diagnosed in clinical stage IV and in average more than 50% of patients who are diagnosed initially with resectable disease will relapse sooner or later.

    Comment?

  12. ARMO BioSciencesa AM0010 Demonstrates Promising Clinical Data as an...Read the original story

    Jun 6, 2016 | Freshnews

    ARMO BioSciences, Inc., a clinical-stage biotechnology company, announced new clinical data on the Company's lead investigational immuno-oncology drug AM0010 as a monotherapy and in combination with an anti-PD-1 monoclonal antibody for the treatment of advanced cancers. These data were presented yesterday at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

    Comment?

  13. ASCO2016: GANYMED Pharmaceuticals AG's IMAB362 Extends Survival In Gastric CancerRead the original story

    Jun 5, 2016 | BioSpace

    IMAB362 nearly doubles survival in patients with the highest levels of Claudin18.2 target MAINZ, Germany, June 5, 2016 /PRNewswire/ -- Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly targeted immunotherapies against cancer, announced outstanding data from its randomized Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting. IMAB362 is a first-in-class monoclonal antibody targeting the cell surface molecule Claudin18.2. The Phase II study in patients with advanced biomarker-positive gastric cancer reached all its endpoints.

    Comment?

  14. Trial shows improved 5 year survival for pancreatic cancer patientsRead the original story w/Photo

    Jun 6, 2016 | Medical News Today

    An extra 13 percent of pancreatic cancer patients will live for at least five years when given a combination of chemotherapy drugs compared with standard treatment, according to the results of a Cancer Research UK trial1 presented at the American Society of Clinical Oncology . Researchers working on the major pancreatic clinical trial say this combination treatment should be the new standard of care for patients with the disease.

    Comment?

  15. ARMO BioSciences' AM0010 Demonstrates Promising Clinical Data as an...Read the original story w/Photo

    Jun 5, 2016 | PR Newswire

    ARMO BioSciences' AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, announced new clinical data on the Company's lead investigational immuno-oncology drug AM0010 as a monotherapy and in combination with an anti-PD-1 monoclonal antibody for the treatment of advanced cancers.

    Comment?

  16. Chemo 318x200Read the original story w/Photo

    Jun 5, 2016 | New Vision

    A combination of two chemotherapy drugs has shown promising results in fighting pancreatic cancer, significantly improving five-year survival rates, according to a European study presented Friday. The trial showed that patients who take the oral drug capecitabine in addition to treatment with the commonly-used intravenous drug gemcitabine after surgical removal of pancreatic cancer survived longer without significant increase in negative side effects.

    Comment?

  17. Ganymeda s IMAB362 Extends Survival in Gastric CancerRead the original story

    Jun 5, 2016 | Freshnews

    Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly targeted immunotherapies against cancer, announced outstanding data from its randomized Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting. IMAB362 is a first-in-class monoclonal antibody targeting the cell surface molecule Claudin18.2. The Phase II study in patients with advanced biomarker-positive gastric cancer reached all its endpoints.

    Comment?

  18. Two-drug regimen shows promise against pancreatic cancerRead the original story w/Photo

    Jun 4, 2016 | Manila Bulletin

    A combination of two chemotherapy drugs has shown promising results in fighting pancreatic cancer, significantly improving five-year survival rates, according to a European study presented Friday. The trial showed that patients who take the oral drug capecitabine in addition to treatment with the commonly-used intravenous drug gemcitabine after surgical removal of pancreatic cancer survived longer without significant increase in negative side effects.

    Comment?

  19. Scientists identify breast cancer's 'Achilles heel' in landmark discoveryRead the original story w/Photo

    Jun 3, 2016 | Daily Mail

    A new study has shed light on why breast cnacer can return years after women appear to be free of it. A stock photo of a young woman self examining her breasts for signs of cancer A study has shed light on why the disease can return years after women appear to be free of it.

    Comment?

  20. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab...Read the original story w/Photo

    Jun 2, 2016 | BioMed Central

    Human epidermal growth factor receptor 2 -positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast cancer, particularly when administered in combination with trastuzumab - however, doxorubicin-related cardiotoxicity has limited its use.

    Comment?